Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% - Should You Sell?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) shares traded down 0.8% during trading on Thursday . The stock traded as low as $3.89 and last traded at $3.94. 9,469 shares traded hands during trading, a decline of 28% from the average session volume of 13,195 shares. The stock had previously closed at $3.97.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They issued a "buy" rating and a $12.00 price objective for the company.

Eupraxia Pharmaceuticals Trading Down 0.8%

The stock has a fifty day moving average price of $3.64 and a 200 day moving average price of $3.47. The firm has a market cap of $141.25 million, a price-to-earnings ratio of -5.47 and a beta of 0.66.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). On average, sell-side analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth about $31,000. Raymond James Financial Inc. bought a new position in Eupraxia Pharmaceuticals in the 4th quarter worth approximately $37,000. Bank of Montreal Can increased its position in Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after buying an additional 7,500 shares during the period. Royal Bank of Canada raised its position in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock valued at $1,125,000 after buying an additional 59,683 shares during the last quarter. Finally, Scotia Capital Inc. lifted its position in shares of Eupraxia Pharmaceuticals by 11.6% in the 1st quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock worth $5,072,000 after acquiring an additional 160,960 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.